Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy–A meta-analysis

Author： Sher Amna   Wu Shenhong  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.50, Iss.7, 2011-10, pp. : 997-1005

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma

By Terheyden Patrick   Hofmann Maja   Weininger M.   Bröcker Eva-B.   Becker Jürgen  

Journal of Cancer Research and Clinical Oncology, Vol. 133, Iss. 11, 2007-11 ,pp. : 897-901

Springer Publishing Company

Access to resources Recommend Favorite

Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis

By            

Molecular and Clinical Oncology, Vol. 3, Iss. 4, 2015-01 ,pp. : 959-967

Science Publishers

Access to resources Recommend Favorite

Associations between vascular endothelial growth factor polymorphisms and prostate cancer risk: a meta-analysis

By Xu Yipeng   Zhu Shaoxing  

Tumor Biology, Vol. 35, Iss. 2, 2014-02 ,pp. : 1307-1311

Springer Publishing Company

Access to resources Recommend Favorite

Vascular endothelial growth factor +936C/T polymorphism and gastric cancer risk: A meta-analysis

By            

Experimental and Therapeutic Medicine, Vol. 2, Iss. 5, 2011-01 ,pp. : 931-936

Spandidos Publications

Access to resources Recommend Favorite

Vascular endothelial growth factor polymorphisms as effect modifiers of oral squamous cell carcinoma risk: A systematic review and meta-analysis

By  

Molecular and Clinical Oncology, Vol. 3, Iss. 2, 2015-01 ,pp. : 347-352

Science Publishers

Access to resources Recommend Favorite